Particulars of the 13 inspection observations that stopped the FDA from approving biosimilars developer Alvotech’s biologic license application (BLA) for AVTOC2 draw a picture of a manufacturing facility seriously out of compliance with good manufacturing practice.
Source: Drug Industry Daily